This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding out more,
Citing increasing demand from doctors to assess diseases close up, the Australian investment news service Stockhead has included Imagion Biosystems (ASX:IBX) among “Ten ASX medical imaging
Imagion Biosystems’ abstract “Detection of HER2+ tumor cells using MagSense® nanoparticles: safety and sensitivity” has been accepted for the 2018 AACR meeting under the organization’s
In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix
The audio file of the December 2017 Investor Update call is now available. Listen here: Visitors wishing to follow along with the visuals can watch
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply
“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017
This video (below) captures the opening minutes of CEO Bob Proulx’s address to the 2016 NobleCon meeting, where he outlines the medical need for a
Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical (“StarFish”), Canada’s largest medical device design, development and contract manufacturing company,